Venus Remedies Limited

526953

INE411B01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:49 30/05/2024 pm IST			5-day change	1st Jan Change
288.2 ^INR	-1.03%		-4.22%	-28.99%

19/03	Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	MT
08/03	Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	MT

Venus Remedies Limited Appoints Brij Mohan Sharma as Additional Independent Non- Executive Director

August 13, 2019 at 06:15 pm IST

Venus Remedies Limited announced the appointment of Mr. Brij Mohan sharma as Additional Independent Non- Executive director of the company with effect from August 13, 2019.

Latest news about Venus Remedies Limited

Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	19/03	MT
Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	08/03	MT
Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Venus Remedies Gets Ukraine Marketing Approval for Chemotherapy Drug, Antibiotics	13/02	MT
Venus Remedies Gets Marketing Authorization in Malta for Two Chemotherapy Drugs	12/01	MT
Venus Remedies Gets Authorization to Market Cancer Drugs in Israel, Colombia	21/12	MT
Indian Equities Clock Sharp Losses on Wednesday Due to Widespread Selling	20/12	MT
Venus Remedies Expands Into Wellness Business	20/12	MT
Venus Remedies Gets Bahrain Marketing Authorization for Enoxaparin	19/12	MT
Indian Equities Score Another Record Highs on Tuesday, Lifted by Ruling Party's State Polls Win	05/12	MT
Venus Remedies Gets Azerbaijan's Marketing Approval for Blood Clot Prevention Drug	05/12	MT
Venus Remedies Gets Marketing Approval for Cancer Drugs in Philippines, Saudi Arabia	01/12	MT
Venus Remedies Limited Receives Market Authorizations in Saudi Arabia and Philippines	01/12	CI
Venus Remedies' Consolidated Profit Jumps in Fiscal Q2	27/11	MT
Venus Remedies Arm Gets Authorization to Market Cancer Drug in UK	26/23/26	MT
Venus Remedies Secures Marketing Approval for Six Key Chemotherapy Drugs in Philippines	16/23/16	MT
Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs	16/23/16	CI
Venus Remedies Launches Antibiotic Elores in Ecuador	12/23/12	MT
Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador	12/23/12	CI
Venus Remedies Gets Marketing Authorization from Serbia for Chemotherapy Drugs	20/23/20	MT
Venus Remedies Limited Extends Its Oncology Portfolio in South Eastern Europe with Serbian Marketing Approval for Gemcitabine and Docetaxel	20/23/20	CI
Venus Remedies Gets Saudi Arabia Marketing Approval for Enoxaparin	28/23/28	MT
Venus Remedies Launches Flagship Drug in Oman	17/23/17	MT
Venus Remedies Launches its R&D Drug Elores, in the $1.4 Billion Pharmaceutical Market in Oman	17/23/17	CI
Venus Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI

Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Companyâs brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.

Sector

Pharmaceuticals

Calendar

30/05/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VENUS REMEDIES LIMITED	-28.99%	4.67Cr
ELI LILLY AND COMPANY	+39.82%	73TCr
NOVO NORDISK A/S	+31.34%	59TCr
JOHNSON & JOHNSON	-7.31%	35TCr
MERCK & CO., INC.	+14.23%	32TCr
ABBVIE INC.	+0.86%	27TCr
ASTRAZENECA PLC	+13.47%	24TCr
ROCHE HOLDING AG	-6.63%	20TCr
NOVARTIS AG	+7.49%	20TCr
AMGEN INC.	+4.51%	16TCr